Between January 1982 and February 1985, 70 breast cancer patients with histologically confirmed axillary node involvement and T1–3a were treated following surgery with a combination of adriamycin, fluorouracil, cyclophosphamide, methotrexate, with or without tamoxifen according to the estrogen and progesterone receptors state. At 60 months of study (median follow-up, 41 months), the estimated proportion remaining disease-free was 62%. The estimated survival rate was 81%. A comparison of the actuarial disease-free and overall survival with data reported in the literature indicates a similar positive effect of adjuvant systemic therapy as described in adjuvant studies using polychemotherapy regimens. Patient acception of chemotherapy regimen was generally good. This can be accounted for because of an adequate emesis control and real compliance of the patients with the oncologist.
Get full access to this article
View all access options for this article.
References
1.
AllenH., BrooksF., JonesS.E., ChaseE., HeusinkveldR.S., GiordanoG.F., KetchelS.J., JacksonR.A., DavisS., MoonT., SalmonS.E.: Adjuvant treatment for stage II (node positive) breast cancer with adriamycin-cyclophosphamide (AC) ± radiotherapy (XRT).In: Adjuvant Therapy of Cancer, III, JonesS.E., SalmonS.E. (eds.), pp. 453–462, Grune and Stratton, New York, 1981.
2.
BonadonnaG., ValagussaP., RossiA., ZucaliR., TanciniG., BajettaE., BrambillaC., De LenaM., Di FronzoG., BanfiA., RilkeF., VeronesiU.: Are surgical adjuvant trials altering the course of breast cancer? Semin.Oncol., 5: 450–464, 1978.
3.
BonadonnaG., RossiA., ValagussaP.: Adjuvant CMF chemotherapy in operable breast cancer: ten years later.World J. Surg., 9: 707–713, 1985.
4.
BonadonnaG., ValagussaP.: Adjuvant chemoendocrine therapy in breast cancer.J. Clin. Oncol., 4: 451–453, 1986.
5.
BonadonnaG., ValagussaP.: Adjuvant systemic therapy for resectable breast cancer.J. Clin. Oncol., 3: 259–275, 1985.
6.
BuzdarA.U., SmithT.L., BlumenscheinG.R., HortobagyiG.N., MarcusC.E., HershE.M., MartinR.G., GehanE.A., FreireichE.J.: Breast cancer adjuvant therapy trials of M.D. Anderson Hospital: results of two studies. In: Adjuvant Therapy of Cancer, IV.JonesS.E., SalmonS.E. (eds.), pp. 217–225, Grune and Stratton, Orlando, 1984.
7.
BuzdarA.U., SmithT.L., BlumenscheinG.R., HortobagyiG.N., YapH., HershE.M., GehanE.A.: Adjuvant therapy for stage II or III breast cancer: UT M.D. Anderson Hospital experience. In: Current Controversies in Breast Cancer, AmesF.C., BlumenscheinG.R., MontagueE.D. (eds.), pp. 169–182, University of Texas Press, Austin, 1984.
8.
DavisB.W., ZavaD.T., LocherG.W., GoldhirschA., HartmannW.H.: Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor.Eur. J. Cancer Clin. Oncol., 20: 374–382, 1984.
9.
FisherB., SlackN., KatrychD., WolmarkN.: Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy.Surg. Gynecol. Obstet., 140: 528–534, 1975.
10.
FisherB., RedmondC., FisherE.R., and participating NSABP Investigators: A summary of findings from NSABP trials of adjuvant therapy.In: Adjuvant Therapy of Cancer, IV.JonesS.E., SalmonS.E. (eds.), pp. 185–194, Grune and Stratton, Orlando, 1984.
11.
FisherB., RedmondC., BrownA., FisherE.R., WolmarkN., BowmanD., PlotkinD., WolterJ., BornsteinR., Legault-PoissonS., SafferE.A., and other NSABP Investigators: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.J. Clin. Oncol., 4: 459–471, 1986.
12.
HoogstratenB., GeorgeS.L., SamalB., RivkinS.B., CostanzaJ.J., BonnetJ.D., ThigpenT., BraineH.: Combination chemotherapy and adriamycin in patients with advanced breast cancer. A southwest oncology group study.Cancer, 38: 13–20, 1976.
13.
HubayC.A., GordonN.H., PearsonO.H., MarshallJ.S., McGuireW.L., and Participating Investigators: Eight-year follow-up of adjuvant therapy for stage II breast cancer.World J. Surg., 9: 738–749, 1985.
14.
JonesS., MoonT., DavisS., ValagussaP., BonadonnaG., PowlesT., RivkinS.: Comparative analysis of selected breast cancer adjuvant trials in relation to the Natural History Data Base (NHDB).In: Adjuvant Therapy of Cancer, III.JonesS.E., SalmonS.E. (eds.), pp. 483–491, Grune and Stratton, New York, 1981.
Ludwing Breast Cancer Study Group: Randomised trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.Lancet, 1: 1253–1256, 1984.
17.
MantelN., HaenszelW.: Statistical aspects of the analysis of data from retrospective studies of disease.J. Natl. Cancer Inst., 22: 719–748, 1959.
18.
MissetJ.L., De VassalF., JasmisC., MussetM., SchwarzenbergL., BelpommeD., PlagneR., Le MevelB., GuerrinJ., JeanneC., MoriceV., DelgadoM., HayatM., MachoverD., RibaudP., MatheG., CholletP., MetzR., FumoleauP., FargeotD., ScheiderM., GagetG.: Five year results of the French adjuvant trial for breast cancer comparing CMF to a combination of adriamycin (ADM), vincristine (VCR), cyclophosphamide (CPM), and 5-fluorouracil (5-FU).In: Adjuvant Therapy of Cancer, IV.JonesS.E., SalmonS.E. (eds.), pp. 243–251, Grune and Stratton, Orlando, 1984.
19.
MoonT., JonesS.E., DavisS.L., BonadonnaG., ValagussaP., VeronesiU., PowlesT.J.: Development of a natural history data base for breast cancer.In: Adjuvant Therapy of Cancer, III.SalmonS.E., JonesS.E. (eds.), pp. 471–481, Grune and Stratton, New York, 1981.
20.
OsborneC.K.: Heterogeneity in hormone receptor status in primary and metastatic breast cancer.Semin. Oncol., 12: 317–326, 1985.
21.
SalmonS.E., JonesS.E.: Studies of the combination of adriamycin and cyclophosphamide (alone or with other agents) for the treatment of breast cancer.Oncology, 36: 40–47, 1979.
22.
ValagussaP., BonadonnaG., VeronesiU.: Patterns of relapse and survival following radical mastectomy. Analysis of 716 cases.Cancer, 41: 1171–1178, 1978.
